Evolent Health (NYSE:EVH - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $650.92 million for the quarter. Parties interested in listening to the company's conference call can do so using this link.
Evolent Health Trading Up 1.0 %
NYSE EVH traded up $0.10 during trading on Friday, hitting $10.07. 1,745,560 shares of the company's stock traded hands, compared to its average volume of 2,244,315. The stock has a fifty day moving average of $10.86 and a two-hundred day moving average of $19.22. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health has a 12-month low of $9.45 and a 12-month high of $35.00. The firm has a market cap of $1.17 billion, a P/E ratio of -11.06 and a beta of 1.45.
Analysts Set New Price Targets
EVH has been the subject of a number of analyst reports. BTIG Research dropped their target price on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating for the company in a report on Tuesday, December 3rd. Needham & Company LLC reiterated a "buy" rating and set a $15.00 target price on shares of Evolent Health in a report on Wednesday. UBS Group dropped their target price on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, January 16th. Canaccord Genuity Group dropped their target price on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Finally, Oppenheimer dropped their target price on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a report on Friday, January 24th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Evolent Health currently has a consensus rating of "Buy" and an average target price of $17.92.
Check Out Our Latest Stock Report on Evolent Health
About Evolent Health
(
Get Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Further Reading
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
